Biotech Values

[DewDiligence]

YMTX -10%/PM on purportedly-positive phase-1b data in PD:

https://www.globenewswire.com/news-release/2021/11/10/2331322/0/en/Yumanity-Therapeutics-Announces-Positive-Top-Line-Results-of-Phase-1b-Clinical-Trial-for-YTX-7739-in-Patients-with-Parkinson-s-Disease-Company-Plans-to-Advance-Program-to-Phase-2.html

As expected, after only 28 days of dosing, there were no statistically significant differences in clinical assessments (UPDRS III, MoCA) or most exploratory biomarkers.

The “as expected” qualifier is not the whole truth.